The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Edwards Lifesciences reported a 13.6% increase in Q2 2026 sales to $1.74 billion, with adjusted EPS reaching $0.78. The growth was driven by robust demand in TAVR sales, which rose 11.3% to $1.26 billion, and a significant 47.3% surge in Transcatheter Mitral and Tricuspid Therapies (TMTT) revenue. Following these strong results, the company has raised its full-year sales guidance.